Drug class provides cardiovascular benefit for all patients with type 2 diabetes

(George Institute for Global Health) All type 2 diabetes patient subgroups are likely to achieve cardiovascular protection from the use of SGLT2 inhibitors, according to a large multi-study review published in the Journal of the American Heart Association.